Company News
Immunome Phase‑3 Trial Shows 84% Risk Reduction
Immunome's phase 3 RINGSIDE trial of varegacestat met primary endpoint, cutting disease progression risk by 84% vs placebo (HR 0.16, p<0.0001).
Confirmed objective response was 56% with varegacestat v
